Investor Relations Captor Therapeutics ®
Notification under Article 69 of the Act on Public Offering - change in a significant block of shares
Current report no. 50/2023
Drafting date: 24 October 2023.
Subject: Notification under Article 69 of the Act on Public Offering - change in a significant block of shares
Legal basis: Article 70(1) of the Public Offering Act - acquisition or disposal of a significant block of shares
The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the "Company"), fulfilling the obligation arising from Art. 70 (1) of the Act on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organised Trading and Public Companies (the "Act on Public Offering"), informs that today the Company received a notification filed pursuant to Art. 69 (1) (1) and 87 (1) (2) (a) of the Act on Public Offering, , from TFI Allianz Polska S.A. (hereinafter: the "Funds’ Manager"), acting for and on behalf of the Funds:
- Allianz Duo FIO,
- Allianz FIO,
- Allianz Inwestycje SFIO,
- Allianz Plan Emerytalny SFIO,
- Allianz SFIO PPK,
- Bezpieczna Jesień SFIO,
(collectively, the "Funds", the "Shareholder"), of the change of the Shareholder's share of the total number of votes in the Company.
As a result of the registration of the series P share issue of Company, of which the Company reported in current report No. 49/2023 of 23 October 2023, the joint level of involvement of the Funds managed by the Funds’ Manager in the total number of votes at the general meeting of shareholders of the Company has changed.
The Funds hold currently a total of 343,483 shares in the Company, representing 7.39% of the share capital, entitling them to 343,483 votes, representing 5.93% of the total number of votes at the Company's general meeting of shareholders.
The Company provides the full text of the notice received as attached.